Aurora Cannabis Inc., CanniMed Therapeutics Inc. and CTT Pharmaceutical Holdings, Inc. announced that the companies have entered into a three-way agreement that provides Aurora, through its ownership of CanniMed, with joint exclusivity on the distribution in Canada of CTT's novel, patented drug delivery technologies. This collaboration includes the licensing by CTT to CanniMed and Aurora of six patents related to cannabinoid delivery for pain management that will enable CanniMed and Aurora to exclusively develop and commercialize this unique, sub-lingual (beneath the tongue) wafer, drug delivery system in Canada. Orally Dissolvable Thin Film ("ODF") Wafers are a proprietary drug delivery mechanism in the form of paper-thin polymer films used as carriers for pharmaceutical agents, with the following benefits: ODF Wafer is taken orally but does not require water or swallowing; ODF Wafers dissolve quickly in the oral cavity (5-15 seconds), with the active ingredient rapidly absorbed and diffused for direct access to the bloodstream; The active ingredient, once absorbed, can bypass the liver's first-pass effect, improving therapeutic outcomes and efficacy through improved bioavailability and facilitates excellent patient compliance; ODF Wafers are suitable for a wide range of patients, including for geriatric and pediatric patients who experience difficulty swallowing.

The companies are currently working together toward obtaining Health Canada approval prior to marketing and distributing the sub-lingual wafer.